Vivo Ventures Fund Vi, L.p. - Net Worth and Insider Trading

Vivo Ventures Fund Vi, L.p. Net Worth

The estimated net worth of Vivo Ventures Fund Vi, L.p. is at least $76 Million dollars as of 2024-11-13. Vivo Ventures Fund Vi, L.p. is the 10% Owner of Sagent Pharmaceuticals Inc and owns about 3,481,652 shares of Sagent Pharmaceuticals Inc (SGNT) stock worth over $76 Million. Vivo Ventures Fund Vi, L.p. is also the 10% Owner of Eiger BioPharmaceuticals Inc and owns about 59,570 shares of Eiger BioPharmaceuticals Inc (EIGRQ) stock worth over $506,345. Details can be seen in Vivo Ventures Fund Vi, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Vivo Ventures Fund Vi, L.p. has not made any transactions after 2016-08-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Vivo Ventures Fund Vi, L.p.

To

Vivo Ventures Fund Vi, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Vivo Ventures Fund Vi, L.p. owns 3 companies in total, including Eiger BioPharmaceuticals Inc (EIGRQ) , Sagent Pharmaceuticals Inc (SGNT) , and KalVista Pharmaceuticals Inc (KALV) .

Click here to see the complete history of Vivo Ventures Fund Vi, L.p.’s form 4 insider trades.

Insider Ownership Summary of Vivo Ventures Fund Vi, L.p.

Ticker Comapny Transaction Date Type of Owner
EIGRQ Eiger BioPharmaceuticals Inc 2016-08-18 10 percent owner
SGNT Sagent Pharmaceuticals Inc 2016-04-21 10 percent owner
KALV KalVista Pharmaceuticals Inc 2015-04-08 10 percent owner

Vivo Ventures Fund Vi, L.p. Latest Holdings Summary

Vivo Ventures Fund Vi, L.p. currently owns a total of 2 stocks. Among these stocks, Vivo Ventures Fund Vi, L.p. owns 3,481,652 shares of Sagent Pharmaceuticals Inc (SGNT) as of April 21, 2016, with a value of $76 Million and a weighting of 99.34%. Vivo Ventures Fund Vi, L.p. also owns 59,570 shares of Eiger BioPharmaceuticals Inc (EIGRQ) as of August 18, 2016, with a value of $506,345 and a weighting of 0.66%.

Latest Holdings of Vivo Ventures Fund Vi, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SGNT Sagent Pharmaceuticals Inc 2016-04-21 3,481,652 21.76 75,760,748
EIGRQ Eiger BioPharmaceuticals Inc 2016-08-18 59,570 8.50 506,345

Holding Weightings of Vivo Ventures Fund Vi, L.p.


Vivo Ventures Fund Vi, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Vivo Ventures Fund Vi, L.p. has made a total of 0 transactions in Sagent Pharmaceuticals Inc (SGNT) over the past 5 years. The most-recent trade in Sagent Pharmaceuticals Inc is the sale of 2,316 shares on April 21, 2016, which brought Vivo Ventures Fund Vi, L.p. around $31,382.

According to the SEC Form 4 filings, Vivo Ventures Fund Vi, L.p. has made a total of 0 transactions in Eiger BioPharmaceuticals Inc (EIGRQ) over the past 5 years. The most-recent trade in Eiger BioPharmaceuticals Inc is the acquisition of 6,250 shares on August 18, 2016, which cost Vivo Ventures Fund Vi, L.p. around $3 Million.

Insider Trading History of Vivo Ventures Fund Vi, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Vivo Ventures Fund Vi, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Vivo Ventures Fund Vi, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Vivo Ventures Fund Vi, L.p. is -15.29%. GuruFocus also compares Vivo Ventures Fund Vi, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Vivo Ventures Fund Vi, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Vivo Ventures Fund Vi, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Vivo Ventures Fund Vi, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -7.2 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -5.01 LIMIT LIMIT LIMIT LIMIT LIMIT

Vivo Ventures Fund Vi, L.p. Ownership Network

Ownership Network List of Vivo Ventures Fund Vi, L.p.

No Data

Ownership Network Relation of Vivo Ventures Fund Vi, L.p.

Insider Network Chart

Vivo Ventures Fund Vi, L.p. Owned Company Details

What does Eiger BioPharmaceuticals Inc do?

Who are the key executives at Eiger BioPharmaceuticals Inc?

Vivo Ventures Fund Vi, L.p. is the 10 percent owner of Eiger BioPharmaceuticals Inc. Other key executives at Eiger BioPharmaceuticals Inc include 10 percent owner Richard A Kayne , 10 percent owner Leen Kawas , and Chief Business Officer Ingrid Choong .

Eiger BioPharmaceuticals Inc (EIGRQ) Insider Trades Summary

Over the past 18 months, Vivo Ventures Fund Vi, L.p. made no insider transaction in Eiger BioPharmaceuticals Inc (EIGRQ). Other recent insider transactions involving Eiger BioPharmaceuticals Inc (EIGRQ) include a net purchase of 278,239 shares made by Richard A Kayne , and a net purchase of 24,332 shares made by Leen Kawas .

In summary, during the past 3 months, insiders sold 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) were sold and 10,086 shares were bought by its insiders, resulting in a net purchase of 10,086 shares.

Eiger BioPharmaceuticals Inc (EIGRQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Eiger BioPharmaceuticals Inc Insider Transactions

No Available Data

Vivo Ventures Fund Vi, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Vivo Ventures Fund Vi, L.p.. You might contact Vivo Ventures Fund Vi, L.p. via mailing address: 575 High Street, Suite 201, Palo Alto Ca 94301.